semaglutide and depression medication Novo Nordisk is suing Eli Lilly over its GLP-1 ads, accusing the rival drugmaker of false advertising for claiming Lilly's Mounjaro Zepbound outperform Novo's Ozempic and Wegovy. MORE BELOW ⬇️ glp-1 ileus lawyer in west

Write the date you first draw from the vial directly on the label with a permanent marker

June 2025: The European Medicines Agencys (EMAs) safety committee concluded that NAION is a very rare potential side effect of semaglutide medicines, like Wegovy

Combining them requires careful alignment under medical supervision to ensure treatment outcomes remain effective

It has caused weeks of nausea that should never have happened

More than 86% of treated participants lost at least 5% of body weight

In the SURMOUNT-5 head-to-head trial ( N Engl J Med , May 2025), tirzepatide produced 20.2% average weight loss compared to 13.7% with semaglutide over 72 weeks a 47% greater relative reduction